WO2010012965A3 - Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer - Google Patents

Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer Download PDF

Info

Publication number
WO2010012965A3
WO2010012965A3 PCT/FR2009/051543 FR2009051543W WO2010012965A3 WO 2010012965 A3 WO2010012965 A3 WO 2010012965A3 FR 2009051543 W FR2009051543 W FR 2009051543W WO 2010012965 A3 WO2010012965 A3 WO 2010012965A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
acts
chemotherapy agent
treatment
intrinsic
Prior art date
Application number
PCT/FR2009/051543
Other languages
English (en)
Other versions
WO2010012965A2 (fr
Inventor
Serge Lebecque
Charles Dumontet
Yves Pacheco
Claire Rodriguez-Lafrasse
Florent Toscano
Yann Estornes
François VIRARD
Isabelle Coste-Invernizzi
Toufic Renno
Original Assignee
Hospices Civils De Lyon
Universite Claude Bernard Lyon I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospices Civils De Lyon, Universite Claude Bernard Lyon I filed Critical Hospices Civils De Lyon
Priority to US13/056,341 priority Critical patent/US20120045523A1/en
Publication of WO2010012965A2 publication Critical patent/WO2010012965A2/fr
Publication of WO2010012965A3 publication Critical patent/WO2010012965A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un médicament comprenant séparément ou ensemble (i) un ligand de TLR3 et (ii) un agent de chimiothérapie agissant sur la voie intrinsèque de l'apoptose, pour une administration, simultanée ou étalée dans le temps dans le traitement du cancer, l'agent de chimiothérapie étant choisi parmi les inhibiteurs de la topoisomérase 2, les agents alkylants dérivés du platine et les inhibiteurs de PI3 kinase.
PCT/FR2009/051543 2008-07-31 2009-07-31 Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer WO2010012965A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/056,341 US20120045523A1 (en) 2008-07-31 2009-07-31 Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic "apoptosis" pathway in the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0855304 2008-07-31
FR0855304A FR2934492B1 (fr) 2008-07-31 2008-07-31 Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.

Publications (2)

Publication Number Publication Date
WO2010012965A2 WO2010012965A2 (fr) 2010-02-04
WO2010012965A3 true WO2010012965A3 (fr) 2010-04-15

Family

ID=40380019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/051543 WO2010012965A2 (fr) 2008-07-31 2009-07-31 Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer

Country Status (3)

Country Link
US (1) US20120045523A1 (fr)
FR (1) FR2934492B1 (fr)
WO (1) WO2010012965A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101781654B1 (ko) 2009-03-12 2017-09-25 제넨테크, 인크. 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
EP2708236A1 (fr) 2012-09-12 2014-03-19 Medizinische Universität Wien Traitement de tumeurs
CA3213217A1 (fr) 2021-04-28 2022-11-03 Raphael Darteil Potentialisation forte d'effets d'agonistes de tlr3 a l'aide d'agonistes de fxr en tant que traitement combine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144985A1 (fr) * 2006-06-16 2007-12-21 Taisho Pharmaceutical Co., Ltd. Utilisation d'un inhibiteur de l'expression du gène rpn2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144985A1 (fr) * 2006-06-16 2007-12-21 Taisho Pharmaceutical Co., Ltd. Utilisation d'un inhibiteur de l'expression du gène rpn2

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADAMS M ET AL: "The rationale for combined chemo/immunotherapy using a TLR3 agonist and tumour-derived exosomes in advanced ovarian cancer", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, 1 January 2005 (2005-01-01), pages 2374 - 2378, XP002517513, ISSN: 0264-410X *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1977, KOVARÍK J ET AL: "Experimental chemotherapy of rat leukemia RBA-Le with cis-diamminedichloroplatinum.", XP002517514, Database accession no. NLM270616 *
MARONE ET AL.: "Targeting phosphoinositide 3-kinase-Moving towards therapy", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 1 January 2008 (2008-01-01) - 31 December 2008 (2008-12-31), pages 159 - 185, XP022425232 *
NEOPLASMA 1977, vol. 24, no. 5, 1977, pages 475 - 486, ISSN: 0028-2685 *

Also Published As

Publication number Publication date
US20120045523A1 (en) 2012-02-23
WO2010012965A2 (fr) 2010-02-04
FR2934492B1 (fr) 2012-08-17
FR2934492A1 (fr) 2010-02-05

Similar Documents

Publication Publication Date Title
TN2009000224A1 (en) Inhibitors of akt activity
WO2009064444A9 (fr) Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2014194254A9 (fr) Traitement anticancer au moyen de modulateurs isoformes de la kinase p13
HK1160779A1 (en) Cdk inhibitor for the treatment of mesothelioma
WO2007084532A3 (fr) Polythérapie faisant appel à des inhibiteurs de la parp
PH12013500801A1 (en) Formulations for parenteral delivery of compounds and uses thereof
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
WO2010031825A3 (fr) Procédés et compositions pour le traitement du cancer
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
WO2006110638A3 (fr) Inhibiteur de l'activite akt
BR112013002541A2 (pt) uso de ligante sigma, combinação de pelo menos um ligante sigma e de pelo menos um composto opióide ou opiato para administração simultânea, separada ou sequencial e método de tratamento de um paciente que sofre de oih associada à terapia opióide
WO2005076888A3 (fr) Therapies anticancereuses
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
WO2010136168A8 (fr) Administration continue de ligands d'intégrines pour le traitement du cancer
WO2005099749A3 (fr) Methodes pour controler une angiogenese et une proliferation cellulaire
WO2007008502A3 (fr) Inhibiteurs de kinases 'points de controle'
WO2010012965A3 (fr) Association d'un ligand de tlr3 et d'un agent de chimiotherapie agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09740425

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09740425

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13056341

Country of ref document: US